Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with t-cell infiltration

Edmund K. Bartlett, Patricia A. Fetsch, Armando C. Filie, Andrea Abati, Seth M. Steinberg, John R. Wunderlich, Donald E. White, Daniel J. Stephens, Francesco M. Marincola, Steven A. Rosenberg, Udai S. Kammula

Research output: Contribution to journalArticle

Abstract

Purpose: Metastasis heterogeneity presents a significant obstacle to the development of targeted cancer therapeutics. In this study, we sought to establish from a large series of human melanoma metastases whether there exists a determined pattern in tumor cellular heterogeneity that may guide the development of future targeted immunotherapies. Experimental Design: From a cohort of 1,514 patients with metastatic melanoma, biopsies were procured over a 17-year period from 3,086 metastatic tumors involving various anatomic sites. To allow specific tumor cell profiling, we used established immunohistochemical methods to perform semiquantitative assessment for a panel of prototypic melanocyte differentiation antigens (MDA), including gp100, MART-1, and tyrosinase. To gain insight into the endogenous host immune response against these tumors, we further characterized tumor cell expression of MHC I and MHC II and, also, the concomitant CD4 + and CD8 + T-cell infiltrate. Results: Tumor cell profiling for MDA expression demonstrated an anatomic site-specific pattern of antigen expression that was highest in brain, intermediate in soft tissues/lymph nodes, and lowest in visceral metastases. Hierarchical clustering analysis supported that melanoma metastases have a phylogenetically determined, rather than a stochastic, pattern of antigen expression that varies by anatomic site. Furthermore, tyrosinase expression was more frequently lost in metastatic sites outside of the brain and was uniquely correlated with both endogenous CD8 + and CD4 + T-cell infiltrates. Conclusion: Site-specific antigen heterogeneity represents a novel attribute for human melanoma metastases that should be considered in future therapy development and when assessing the responsiveness to antigen-specific immunotherapies.

Original languageEnglish (US)
Pages (from-to)2607-2616
Number of pages10
JournalClinical Cancer Research
Volume20
Issue number10
DOIs
StatePublished - May 15 2014
Externally publishedYes

Fingerprint

Melanoma
Neoplasm Metastasis
Antigens
Neoplasms
Monophenol Monooxygenase
Immunotherapy
gp100 Melanoma Antigen
T-Lymphocytes
Melanocytes
Differentiation Antigens
Brain
Cluster Analysis
Research Design
Lymph Nodes
Biopsy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Bartlett, E. K., Fetsch, P. A., Filie, A. C., Abati, A., Steinberg, S. M., Wunderlich, J. R., ... Kammula, U. S. (2014). Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with t-cell infiltration. Clinical Cancer Research, 20(10), 2607-2616. https://doi.org/10.1158/1078-0432.CCR-13-2690

Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with t-cell infiltration. / Bartlett, Edmund K.; Fetsch, Patricia A.; Filie, Armando C.; Abati, Andrea; Steinberg, Seth M.; Wunderlich, John R.; White, Donald E.; Stephens, Daniel J.; Marincola, Francesco M.; Rosenberg, Steven A.; Kammula, Udai S.

In: Clinical Cancer Research, Vol. 20, No. 10, 15.05.2014, p. 2607-2616.

Research output: Contribution to journalArticle

Bartlett, EK, Fetsch, PA, Filie, AC, Abati, A, Steinberg, SM, Wunderlich, JR, White, DE, Stephens, DJ, Marincola, FM, Rosenberg, SA & Kammula, US 2014, 'Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with t-cell infiltration', Clinical Cancer Research, vol. 20, no. 10, pp. 2607-2616. https://doi.org/10.1158/1078-0432.CCR-13-2690
Bartlett, Edmund K. ; Fetsch, Patricia A. ; Filie, Armando C. ; Abati, Andrea ; Steinberg, Seth M. ; Wunderlich, John R. ; White, Donald E. ; Stephens, Daniel J. ; Marincola, Francesco M. ; Rosenberg, Steven A. ; Kammula, Udai S. / Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with t-cell infiltration. In: Clinical Cancer Research. 2014 ; Vol. 20, No. 10. pp. 2607-2616.
@article{82efddbc958f40b6b0a8719ae6447a66,
title = "Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with t-cell infiltration",
abstract = "Purpose: Metastasis heterogeneity presents a significant obstacle to the development of targeted cancer therapeutics. In this study, we sought to establish from a large series of human melanoma metastases whether there exists a determined pattern in tumor cellular heterogeneity that may guide the development of future targeted immunotherapies. Experimental Design: From a cohort of 1,514 patients with metastatic melanoma, biopsies were procured over a 17-year period from 3,086 metastatic tumors involving various anatomic sites. To allow specific tumor cell profiling, we used established immunohistochemical methods to perform semiquantitative assessment for a panel of prototypic melanocyte differentiation antigens (MDA), including gp100, MART-1, and tyrosinase. To gain insight into the endogenous host immune response against these tumors, we further characterized tumor cell expression of MHC I and MHC II and, also, the concomitant CD4 + and CD8 + T-cell infiltrate. Results: Tumor cell profiling for MDA expression demonstrated an anatomic site-specific pattern of antigen expression that was highest in brain, intermediate in soft tissues/lymph nodes, and lowest in visceral metastases. Hierarchical clustering analysis supported that melanoma metastases have a phylogenetically determined, rather than a stochastic, pattern of antigen expression that varies by anatomic site. Furthermore, tyrosinase expression was more frequently lost in metastatic sites outside of the brain and was uniquely correlated with both endogenous CD8 + and CD4 + T-cell infiltrates. Conclusion: Site-specific antigen heterogeneity represents a novel attribute for human melanoma metastases that should be considered in future therapy development and when assessing the responsiveness to antigen-specific immunotherapies.",
author = "Bartlett, {Edmund K.} and Fetsch, {Patricia A.} and Filie, {Armando C.} and Andrea Abati and Steinberg, {Seth M.} and Wunderlich, {John R.} and White, {Donald E.} and Stephens, {Daniel J.} and Marincola, {Francesco M.} and Rosenberg, {Steven A.} and Kammula, {Udai S.}",
year = "2014",
month = "5",
day = "15",
doi = "10.1158/1078-0432.CCR-13-2690",
language = "English (US)",
volume = "20",
pages = "2607--2616",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with t-cell infiltration

AU - Bartlett, Edmund K.

AU - Fetsch, Patricia A.

AU - Filie, Armando C.

AU - Abati, Andrea

AU - Steinberg, Seth M.

AU - Wunderlich, John R.

AU - White, Donald E.

AU - Stephens, Daniel J.

AU - Marincola, Francesco M.

AU - Rosenberg, Steven A.

AU - Kammula, Udai S.

PY - 2014/5/15

Y1 - 2014/5/15

N2 - Purpose: Metastasis heterogeneity presents a significant obstacle to the development of targeted cancer therapeutics. In this study, we sought to establish from a large series of human melanoma metastases whether there exists a determined pattern in tumor cellular heterogeneity that may guide the development of future targeted immunotherapies. Experimental Design: From a cohort of 1,514 patients with metastatic melanoma, biopsies were procured over a 17-year period from 3,086 metastatic tumors involving various anatomic sites. To allow specific tumor cell profiling, we used established immunohistochemical methods to perform semiquantitative assessment for a panel of prototypic melanocyte differentiation antigens (MDA), including gp100, MART-1, and tyrosinase. To gain insight into the endogenous host immune response against these tumors, we further characterized tumor cell expression of MHC I and MHC II and, also, the concomitant CD4 + and CD8 + T-cell infiltrate. Results: Tumor cell profiling for MDA expression demonstrated an anatomic site-specific pattern of antigen expression that was highest in brain, intermediate in soft tissues/lymph nodes, and lowest in visceral metastases. Hierarchical clustering analysis supported that melanoma metastases have a phylogenetically determined, rather than a stochastic, pattern of antigen expression that varies by anatomic site. Furthermore, tyrosinase expression was more frequently lost in metastatic sites outside of the brain and was uniquely correlated with both endogenous CD8 + and CD4 + T-cell infiltrates. Conclusion: Site-specific antigen heterogeneity represents a novel attribute for human melanoma metastases that should be considered in future therapy development and when assessing the responsiveness to antigen-specific immunotherapies.

AB - Purpose: Metastasis heterogeneity presents a significant obstacle to the development of targeted cancer therapeutics. In this study, we sought to establish from a large series of human melanoma metastases whether there exists a determined pattern in tumor cellular heterogeneity that may guide the development of future targeted immunotherapies. Experimental Design: From a cohort of 1,514 patients with metastatic melanoma, biopsies were procured over a 17-year period from 3,086 metastatic tumors involving various anatomic sites. To allow specific tumor cell profiling, we used established immunohistochemical methods to perform semiquantitative assessment for a panel of prototypic melanocyte differentiation antigens (MDA), including gp100, MART-1, and tyrosinase. To gain insight into the endogenous host immune response against these tumors, we further characterized tumor cell expression of MHC I and MHC II and, also, the concomitant CD4 + and CD8 + T-cell infiltrate. Results: Tumor cell profiling for MDA expression demonstrated an anatomic site-specific pattern of antigen expression that was highest in brain, intermediate in soft tissues/lymph nodes, and lowest in visceral metastases. Hierarchical clustering analysis supported that melanoma metastases have a phylogenetically determined, rather than a stochastic, pattern of antigen expression that varies by anatomic site. Furthermore, tyrosinase expression was more frequently lost in metastatic sites outside of the brain and was uniquely correlated with both endogenous CD8 + and CD4 + T-cell infiltrates. Conclusion: Site-specific antigen heterogeneity represents a novel attribute for human melanoma metastases that should be considered in future therapy development and when assessing the responsiveness to antigen-specific immunotherapies.

UR - http://www.scopus.com/inward/record.url?scp=84901049529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901049529&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-2690

DO - 10.1158/1078-0432.CCR-13-2690

M3 - Article

C2 - 24647571

AN - SCOPUS:84901049529

VL - 20

SP - 2607

EP - 2616

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -